The comparative effects of erythromycin and amikacin on acute respiratory<i>Pseudomonas aeruginosa</i>infection

Yazdanian, Mohsen; Barzegar, Peyman Esmaeili Fard; Ranjbar, Reza; Tahmasebi, Elahe; Tebyanian, Hamid; Barzegar, Keyvan Esmaeili Fard; Hayati, None Farhad Zadeh; Farjanikish, Ghasem

doi:10.1002/vms3.991

Cited by 2 publications

(1 citation statement)

References 37 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Since the macrolides azithromycin and erythromycin are active on other strains of P. aeruginosa, it is reasonable to assume that the results concerning spiramycin can be extended to different strains of P. aeruginosa. For example, azithromycin and erythromycin are active against P. aeruginosa PAO1 [ 83 , 84 , 85 , 86 , 87 ] and against various clinical isolates [ 85 , 88 ]. In addition, spiramycin forms non-host-guest complexes with methyl-β-cyclodextrin; therefore, these complexes could be used as antibiotic delivery systems as already proposed in the case of other macrolides [ 89 , 90 , 91 ].…”

Section: Discussionmentioning

confidence: 99%

Spiramycin Disarms Pseudomonas aeruginosa without Inhibiting Growth

et al. 2023

View full text Add to dashboard Cite

Spiramycin is a 16-membered macrolide antibiotic currently used in therapy to treat infections caused by Gram-positive bacteria responsible for respiratory tract infections, and it is also effective against some Gram-negative bacteria and against Toxoplasma spp. In contrast, Pseudomonas aeruginosa, which is one of the pathogens of most concern globally, is intrinsically resistant to spiramycin. In this study we show that spiramycin inhibits the expression of virulence determinants in P. aeruginosa in the absence of any significant effect on bacterial multiplication. In vitro experiments demonstrated that production of pyoverdine and pyocyanin by an environmental strain of P. aeruginosa was markedly reduced in the presence of spiramycin, as were biofilm formation, swarming motility, and rhamnolipid production. Moreover, treatment of P. aeruginosa with spiramycin sensitized the bacterium to H2O2 exposure. The ability of spiramycin to dampen the virulence of the P. aeruginosa strain was confirmed in a Galleria mellonella animal model. The results demonstrated that when G. mellonella larvae were infected with P. aeruginosa, the mortality after 24 h was >90%. In contrast, when the spiramycin was injected together with the bacterium, the mortality dropped to about 50%. Furthermore, marked reduction in transcript levels of the antimicrobial peptides gallerimycin, gloverin and moricin, and lysozyme was found in G. mellonella larvae infected with P. aeruginosa and treated with spiramycin, compared to the larvae infected without spiramycin treatment suggesting an immunomodulatory activity of spiramycin. These results lay the foundation for clinical studies to investigate the possibility of using the spiramycin as an anti-virulence and anti-inflammatory drug for a more effective treatment of P. aeruginosa infections, in combination with other antibiotics.

show abstract

Section: Discussionmentioning

confidence: 99%

Spiramycin Disarms Pseudomonas aeruginosa without Inhibiting Growth

et al. 2023

View full text Add to dashboard Cite

show abstract

The comparative effects of erythromycin and amikacin on acute respiratoryPseudomonas aeruginosainfection

Yazdanian

Barzegar

Ranjbar

et al. 2022

Veterinary Medicine & Sci

View full text Add to dashboard Cite

Background: One of the most common causes of pneumonia is Pseudomonas aeruginosa (P. aeruginosa). As with other microbial pathogens, this bacterium tends to develop resistance to various antibiotics. Amikacin and erythromycin, which are from the aminoglycoside and macrolide antibiotic families, are used to treat respiratory infections caused by P. aeruginosa.Objectives: This study explored whether amikacin, erythromycin or a combination of both works better against P. aeruginosa acute lung infection.Methods: For this study, 32 rats were used. The trachea of rats was exposed aseptically and their lung was infected with P. aeruginosa through trachea. Then, according to the group, they received amikacin, erythromycin or a combination of both for 1 week.Finally, they were euthanised on the 3rd and 7th days post-infection. The macroscopic and microscopic evaluations of the lungs, kidney and liver were performed. The right lung was collected for in vivo bacteriological analysis. Results:The amikacin group (A group) had a statistically significantly lower macroscopic and microscopic scores than the other groups (p < 0.05). In vivo bacteriological test revealed that the A group had significantly lower lung bacterial load (p < 0.05). Conclusions:In summary, it was concluded that amikacin could help alleviate the respiratory infection caused by P. aeruginosa solely, and it was more effective than erythromycin.

show abstract

The comparative effects of erythromycin and amikacin on acute respiratoryPseudomonas aeruginosainfection

Cited by 2 publications

References 37 publications

Spiramycin Disarms Pseudomonas aeruginosa without Inhibiting Growth

Spiramycin Disarms Pseudomonas aeruginosa without Inhibiting Growth

The comparative effects of erythromycin and amikacin on acute respiratoryPseudomonas aeruginosainfection

Contact Info

Product

Resources

About